PFE Jan 2024 52.500 call
| Previous Close | 0.3800 |
| Open | 0.3900 |
| Bid | 0.3700 |
| Ask | 0.4100 |
| Strike | 52.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.3700 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 9.2k |
- Motley Fool
If You Invested $25,000 in Pfizer in 2020, This Is How Much You Would Have Today
Investing in top COVID-19 vaccine maker Pfizer (NYSE: PFE) seems like it should have made you rich if you bought the stock in March 2020. On March 2, 2020, Pfizer's stock was selling for $33 a share. It would be nearly a year before Pfizer had an approved COVID-19 vaccine, which was produced in partnership with BioNTech.
- Motley Fool
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor. The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.
- Reuters
UPDATE 4-J&J bows out of RSV vaccine race after scrapping trial
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. The drugmaker, which started the global study in 2021 in more than 27,000 adults aged 60 years and older, did not provide any further details about the trial.
